Interview Intersection: Expert Interviews From April 2025

Melinda Gooderham, MD, discussed delgocitinib cream’s safety and systemic exposure for chronic hand eczema at the 2025 AAD Annual Meeting. She confirmed minimal systemic absorption, even with maximal use, supporting the product's safety profile. Gooderham emphasized the importance of global regulatory approvals, additional safety data, and future comparative studies to guide prescribing decisions. She also highlighted the potential for off-label use for other eczema types and the need for real-world data on delgocitinib's long-term effectiveness.